doisynoestrol | 5936-09-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: doisynoestrol
• 英文别名: ent-3-methoxy-16.17-seco-estrapentaen-(A.B)-oic acid-(18)；(1R)-7-Methoxy-2t-methyl-1r-aethyl-1.2.3.4-tetrahydro-phenanthren-carbonsaeure-(2c)；ent-3-Methoxy-16.17-seco-oestrapentaen-(A.B)-saeure-(18)；ent-3-Methoxy-16.17-seco-oestrapentaen-(1.3.5.7.9)-saeure-(18)；(1R,2S)-1-ethyl-7-methoxy-2-methyl-1,2,3,4-tetrahydrophenanthrene-2-carboxylic acid；(1R,2S)-1-ethyl-7-methoxy-2-methyl-3,4-dihydro-1H-phenanthrene-2-carboxylic acid
• CAS: 5936-09-4
• 化学式: C₁₉H₂₂O₃
• 分子量: 298.382
• InChiKey: HZZSXUIUESWVSS-MJGOQNOKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  doisynoestrol 在 氢溴酸 、 溶剂黄146 作用下， 生成 (+/-)-Z-Bisdehydrodoisynolic acid
  参考文献：
  名称：

  关于类固醇。第52次沟通。n-双脱氢-杜仲异氰酸的外消旋物的裂解。关于雌激素羧酸X

  摘要：

  DOI：

  10.1002/hlca.19460290535
• 作为产物：
  描述：

  (ent-3-methoxy-16.17-seco-estrapentaen-(1.3.5.7.9)-oic acid-(18))-((1R)-menthyl ester) 在 丙醇 、 氢氧化钾 作用下， 生成 doisynoestrol
  参考文献：
  名称：

  关于类固醇。第52次沟通。n-双脱氢-杜仲异氰酸的外消旋物的裂解。关于雌激素羧酸X

  摘要：

  DOI：

  10.1002/hlca.19460290535

文献信息

• Inhibiting proliferation of cancer cells
  申请人：Tufts University

  公开号：US20020123080A1

  公开（公告）日：2002-09-05

  A method of testing cancer cells is described. Assays are provided for determining the potential for inhibiting cancer cells proliferation using albumin-derived peptides. The methods of the present invention allow for drug screening as well as for evaluation of biopsied tumors.

  描述了一种检测癌细胞的方法。提供了利用白蛋白衍生肽确定抑制癌细胞增殖潜力的检测方法。本发明的方法可用于药物筛选以及活检肿瘤的评估。
• Therapeutic applications of estrogenic carboxylic acids
  申请人：Southern Illinois University

  公开号：US20040116398A1

  公开（公告）日：2004-06-17

  Provided are methods employing estrogenic compounds for: repressing weight gain or reducing weight in male patients; treating or preventing prostate cancer and peri- or post-menopausal symptoms; treating estrogen-responsive conditions that no longer respond to treatment with conventional steroidal estrogens; treating or preventing estrogen-responsive uterine cancer, breast cancer, and ovarian follicle atresia; inducing ovulation to increase fertility; oral contraception; treating or preventing diseases or conditions caused or prolonged by free radicals; treating or preventing cardiovascular disease, hyperlipidemia or hypercholesterolemia, and hyperglycemia; improving body fat distribution; and treating or preventing Alzheimer's disease, osteoporosis, and pattern baldness. Also provided are methods for treating or preventing prostatic diseases including benign prostate hyperplasia and other related conditions, androgen-responsive pathological conditions in males, and methods for male birth control and chemical castration, employing estrogenic carboxylic acids.

  本发明提供了采用雌激素化合物的方法，用于抑制男性患者体重增加或减轻体重；治疗或预防前列腺癌和围绝经期或绝经后症状；治疗对传统甾体雌激素治疗不再有反应的雌激素反应性疾病；治疗或预防雌激素反应性子宫癌、乳腺癌和卵巢滤泡闭锁；诱导排卵以提高生育能力；口服避孕药；治疗或预防由自由基引起或延长的疾病或病症；治疗或预防心血管疾病、高脂血症或高胆固醇血症和高血糖症；改善体内脂肪分布；以及治疗或预防老年痴呆症、骨质疏松症和斑秃。此外，还提供了利用雌激素羧酸治疗或预防前列腺疾病（包括良性前列腺增生和其他相关疾病）、男性雄激素反应性病理状况以及男性节育和化学阉割的方法。
• Heer; Billeter; Miescher, Helvetica Chimica Acta, 1945, vol. 28, p. 991,1003
  作者：Heer、Billeter、Miescher

  DOI：——

  日期：——
• Compounds exhibiting efflux inhibitor activity and composition and uses thereof
  申请人：Wempe Fitzpatrick Michael

  公开号：US20070254859A1

  公开（公告）日：2007-11-01

  At least one compound chosen from compounds of Formula I: a pharmaceutically acceptable salt or ester thereof, a solvate thereof, a chelate thereof, a non-covalent complex thereof, a prodrug thereof, and mixtures of any of the foregoing, wherein: n is a number from 1 to 900, wherein the individual units may be the same or different; W is chosen from alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl and substituted aralkyl; each of R 2 , R 3 , R 4 and R 5 is independently chosen from —H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl and substituted aralkyl; Z′ is chosen from —O—, —N—, —NO—, —NR 4 —, —S—, —SO— and —SO 2 —, wherein R 4 is defined as above; each of X, X′, Y and Z is independently chosen from —CR 4 R 5 —, —NH—, —NR 4 —, —NO—, —O—, —NOR 4 —, —S—, —SO—, —SO 2 —, wherein R 4 and R 5 are defined as above; R 1 is chosen from a tocopherol, a steroid and a flavonoid; and R 6 is chosen from any R 1 , alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl and substituted aralkyl.
• Compositions, Methods and Uses for Treating Gender-Biased Immune Disorders
  申请人：Biocopea Limited

  公开号：US20160008376A1

  公开（公告）日：2016-01-14

  The present specification discloses compositions comprising at least one therapeutic compound capable of modulating a level and/or activity of a hormone and methods and uses for treating a gender-biased immune disorder using such compositions.